Drugs kill tumors not only by inducing self-destructive processes inside cancer cells but also by reshaping the tumor immune microenvironment and mobilizing the anti-tumor immunity of the human immune system. Immunogenic cell death patterns, such as ferroptosis, necroptosis, and pyroptosis, are reported to inflame the tumor microenvironment and play a pivotal role in cancer treatment, particularly in cancer immunotherapy. How to utilize drug-induced immunogenic cell death to maximize treatment efficiency is of great significance. However, the co-existence of immunogenic and non-immunogenic cell death patterns even under the same drug treatment and the switch between different cell death patterns in various treatment settings makes the utilization of the anti-tumor immune response triggered by cell death more complicated. Therefore, an In-depth understanding of the mechanism of drug-induced immunogenic cell death patterns and the development of optimal drug combination therapies to maximize treatment efficiency are critical and valuable.
In light of the above-mentioned challenges, the current Research Topic focuses on recent advancements in the research of immunogenic cell death patterns induced by anti-cancer drugs and their potential implications in anti-cancer treatment. In particular, we are interested in screening and designing drugs or drug combinations that trigger the most powerful anti-cancer immune response by inducing immunogenic cell death. The identification of biomarkers of immunogenic cell death induced by anticancer drugs is also encouraged. Review articles on the molecular mechanisms of immunogenic cell death patterns and cross-talk between them are welcomed for submission as well.
• Screening, design, and evaluation of novel anticancer agents or drug combinations that are powerful to induce immunogenic cell death.
• Biomarkers for identification of immunogenic cell death induced by anti-cancer drugs or drug combinations.
• Mechanism study of various cell death patterns induced by drugs in cancer treatment.
• Crosstalk and inter-switch among different cell death patterns.
• Mechanisms of overcoming drug resistance by inducing various immunogenic cell death.
• Reshape of tumor immune micro-environment and their implications on the response to anti-cancer treatment
Drugs kill tumors not only by inducing self-destructive processes inside cancer cells but also by reshaping the tumor immune microenvironment and mobilizing the anti-tumor immunity of the human immune system. Immunogenic cell death patterns, such as ferroptosis, necroptosis, and pyroptosis, are reported to inflame the tumor microenvironment and play a pivotal role in cancer treatment, particularly in cancer immunotherapy. How to utilize drug-induced immunogenic cell death to maximize treatment efficiency is of great significance. However, the co-existence of immunogenic and non-immunogenic cell death patterns even under the same drug treatment and the switch between different cell death patterns in various treatment settings makes the utilization of the anti-tumor immune response triggered by cell death more complicated. Therefore, an In-depth understanding of the mechanism of drug-induced immunogenic cell death patterns and the development of optimal drug combination therapies to maximize treatment efficiency are critical and valuable.
In light of the above-mentioned challenges, the current Research Topic focuses on recent advancements in the research of immunogenic cell death patterns induced by anti-cancer drugs and their potential implications in anti-cancer treatment. In particular, we are interested in screening and designing drugs or drug combinations that trigger the most powerful anti-cancer immune response by inducing immunogenic cell death. The identification of biomarkers of immunogenic cell death induced by anticancer drugs is also encouraged. Review articles on the molecular mechanisms of immunogenic cell death patterns and cross-talk between them are welcomed for submission as well.
• Screening, design, and evaluation of novel anticancer agents or drug combinations that are powerful to induce immunogenic cell death.
• Biomarkers for identification of immunogenic cell death induced by anti-cancer drugs or drug combinations.
• Mechanism study of various cell death patterns induced by drugs in cancer treatment.
• Crosstalk and inter-switch among different cell death patterns.
• Mechanisms of overcoming drug resistance by inducing various immunogenic cell death.
• Reshape of tumor immune micro-environment and their implications on the response to anti-cancer treatment
